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Rezumat
Noi posibilităţi de tratament al pancreatitei cornice cu 
preparatul Liveria IC
Acest studiu a examinat pacienţii cu pancreatită cronică. 
Se demonstrează efi cienţa preparatului Liveria IC, inclus 
în tratamentul tradiţional al pancreatitei cronice, în ceea 
ce priveşte diminuarea sindroamelor dolor şi dispeptic, 
precum şi în scăderea indicilor izoamilazei pancreatice în 
sânge şi urină.
Cuvinte-cheie: pancreatită cronică, durere, dispepsie, 
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Резюме
Новые возможности лечения хронического панкреа-
тита с использованием препарата Ливерия IC
Нами обследованы пациенты с хроническим панкреати-
том. Исследование показало эффективность включения 
в традиционную терапию хронического панкреатита 
препарата Ливерия IC относительно уменьшения боле-
вого и деспептических синдромов, а также показателей 
панкреатической изоамилазы крови и мочи.
Ключевые слова: хронический панкреатит, боль, дис-
пепсия, панкреатическая изоамилаза, Ливерия IC
Introduction
In many patients chronic pancreatitis results 
from a complex of environmental factors (alcohol, 
cigarettes smoking and occupational chemicals), 
some of patients have genetic, hereditary or autoim-
mune nature of disease. The alcoholic nature of the 
chronic pancreatitis dominate not only in Ukraine 
but in Europe also, and chronic alcohol consumpti-
on associated with 38–94% of cases of pancreatitis 
in the developed countries, but is now increasing 
worldwide due to growing consumption of alcohol 
in each nation [8]. About 20% of men and 9% of 
women admit to hospitals with various diseases 
of alcoholic etiology in Europe [3, 4, 5, 8]. It is well 
known that increase spread of chronic pancreatitis in 
Ukraine, associated with rise of alcohol consumption, 
so we have a great interest to asses and improve the 
efficiency of the treatment of patients with chronic 
pancreatitis [3, 6, 9].
According the different sources drug Liveria IC 
showed sufficient efficacy in the treatment of chronic 
hepatitis of various, especially of alcoholic etiology, 
that’s why we had great interest to evaluate the effi-
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cacy of Liveria IC in patients with chronic pancreatitis 
[7]. Liveria IC (1 tablet includes 0, 5 gr. of metadoxin) 
has anxiolytic, hepatoprotective, desintoxicate, anti-
fibrotic, anti-oxidant and anti-depressive effect [7].
Aim of investigation was to assess the efficacy 
of the drug Liveria IC on the dynamic of abdominal 
pain, dyspepsia and biochemical data, such as pan-
creatic isoamylase (p-isoamylase) in blood and urine 
in patients with chronic pancreatitis.
Materials and methods
We investigated 72 patients with chronic 
pancreatitis, 49 (68.1%) of them had chronic alco-
holic pancreatitis. Main group include 37 patients 
with chronic pancreatitis who received traditional 
therapy with antisecretory, spazmolitic, enzyme 
therapy, whom had been added Liveria IC 1tablete 2 
times per day 15–30 minutes before meals for three 
months. In the comparison group were included 
35 patients with chronic pancreatitis who received 
only traditional therapy of chronic pancreatitis. A 
control group included 30 healthy persons. Before 
and after treatment we assessed the dynamics of 
pain , dispeptic syndrome, indicators of pancreatic 
isoamylase in blood and urine.
Severity of complains and painfulness of palpa-
tion we estimate with index of average severity of 
manifestation (ASM) [2]. We used semiquantitative 
scale:
0 score – there are no manifestations;
1 score – minimal manifestation;
2 scores – moderate manifestations;
3 scores – significant manifestation.
In view of the scale we calculate ASM of clinical 
manifestations by formula:
dcba
cbaASM +++
++= 32 ,
where ASM is the average severity of manifes-
tations;
a – the number of patients with manifestation of 
symptoms with 1 score;
b – the number of patients with manifestation of 
symptoms with 2 scores;
c – the number of patients with manifestation of 
symptoms with 3 scores;
d – the number of patients with no symptoms.
Level of p-izoamilase conducted with Vitalab 
Analyzer Flexor (Netherlands) using sets firm Lache-
ma (Czech Republic).
Results and discussion
The leading symptom of all examined patients 
was abdominal pain. Most common location of pain 
was – epigastric region and both hypochondrium 
aria – 24 (33.3%) patients. Pain in epigastric region 
and right hypochondrium in 15 (20.8%) patients, 
in the right hypochondrium only – 10 (13.9%) pati-
ents, epigastric region and left hypochondrium – 11 
(15.3%) patients, only in epigastric region – 4 (5.6%) 
patients, only in the left hypochondrium – 8 (11.1%) 
patients.
In the main group patients before treatment 
dominated moderate abdominal pain – 18 (48.7%) 
patients; the intensity of the pain was minimal at 
11 (29.7%) patients, significant – 8 (21.6%) patients. 
ASM of pain syndrome in the main group before the 
treatment was 1.92. In the comparison group the 
intensity of the pain was similar and determined 
18 (51.4%), 10 (28.6%) and 7 (20.0%) of patients 
correspondently. The ASM of this syndrome in the 
comparison group was 1.91.
Before treatment dyspepsia was at all examined 
patients. 15 (40.6%) patients of main group had in-
tensive dyspepsia, 9 (24.3%) – moderate, 13 (35.1%) 
– minimal dyspepsia. ASM of dyspeptic syndrome 
in this group was 2.05, in the comparison group the 
intensity of this syndrome was determined respecti-
vely by 16 (45.7%), 12 (34.3%) and 7 (20.0%) patients. 
ASM of dispeptic syndrome in the comparison group 
before the treatment amounted 2.26.
After treatment dynamics of clinical manifes-
tations was more pronounced in patients of main 
group. So, ASM of pain syndrome after treatment 
in the main group was 0.91, unlike the comparison 
group was 1.53, 1.68 times higher. The most effective 
was main variant of treatment concern the dyspeptic 
syndrome too. After the treatment the ASM of this 
syndrome in patients of main group was 0.99 and in 
comparison group was 1.57, so 1.59 times higher.
More significant dynamics of p-isoamilase in 
blood and urine was also in the main group unlike 
comparison group patients. P-isoamilase in blood 
was 2.05±0.14 mccat/l before treatment in main 
group patients and after treatment was 0.99±0.08 
mccat/l (p<0.05) and in the comparison group pa-
tients before treatment was 1.39±0.08 mccat/l and 
after 1.02±0.12 mccat/l (p>0.05), in healthy persons 
was 0.87±0.13/l mccat. P-isoamilase in urine in 
patients of the main group before treatment was 
7.05±0.25 mccat/l after treatment was 4.30±0.27 
mccat/l (p<0.05) and in the comparison group 
patients 6.53±0.21 mccat/l before treatment and 
5.26±0.58 mccat/l (p>0.05) after, in healthy persons 
was 3.32±0.39 mccat/l.
Conclusion
Treatment of patients with chronic pancreatitis 
with Liveria IC inclusion leads to reduction of insen-
sitivity of pain, dyspepsia and positive dynamics of 
such biochemical data like pancreatic isoamylase in 
blood and urine.
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